Ozempic face is real, but TikTok is making it worse than it is

What did @liftwithsel actually say?

Honestly, not much. The transcript from this video is a repeated, nonsensical phrase: "I'm going to show you how to make a new video." Twice. That's it. Whatever was intended here, the actual spoken content delivers zero medical claims, zero GLP-1 information, and zero context about "Ozempic face" beyond the hashtag itself.

The caption reads "Schönling" (a German word roughly translating to "pretty boy" or "good-looking one") paired with the hashtag #ozempicface. So the framing suggests this is about the physical appearance changes associated with GLP-1 receptor agonist use, but the creator never actually articulates that claim out loud. We're essentially fact-checking a hashtag and a vibe.

That said, the topic the video points toward, "Ozempic face," is worth taking seriously. It's a real phenomenon that real patients ask about, and the social media conversation around it is frequently misleading in both directions.

Does the science back up the "Ozempic face" concept?

Yes, partially, but the popular framing oversimplifies what's actually happening. "Ozempic face" refers to the facial volume loss and increased skin laxity some patients experience during rapid weight loss on GLP-1 receptor agonists like semaglutide or tirzepatide. The science supports the phenomenon, but not the assumption that it's uniquely caused by the drug itself.

A 2023 commentary in JAMA Dermatology by Hwang and colleagues noted that facial fat loss during significant weight reduction, regardless of method, leads to similar aesthetic changes. The GLP-1 drugs don't specifically target facial fat. They accelerate or enable the weight loss that causes it. Research published by Wilding et al. (2021, NEJM) in the STEP 1 trial showed mean weight loss of around 14.9% body weight on semaglutide 2.4mg, which is substantial enough to produce visible volume changes in the face.

There is also emerging discussion about whether rapid weight loss, versus gradual loss, worsens skin laxity outcomes. The evidence here is preliminary and largely observational.

What did @liftwithsel get wrong, or right?

Since the transcript contains no actual claims, there's nothing to directly correct. But the framing via hashtag perpetuates a few common misconceptions worth addressing.

First, calling it "Ozempic face" implies the drug causes the effect, when the cause is the weight loss. A person who lost the same amount of weight through caloric restriction alone would likely see similar changes. Blaming the medication is imprecise at best and misleading at worst for patients making treatment decisions.

Second, the aesthetic framing can discourage people from pursuing clinically appropriate treatment. A 2022 meta-analysis by Shi et al. in Diabetes, Obesity and Metabolism found GLP-1 receptor agonists significantly reduced cardiovascular risk markers alongside weight. Trading that off because of concerns about facial appearance is a conversation that deserves nuance, not a viral caption.

The video neither earns credit nor draws a clear penalty. It's essentially a null content event wrapped in a trending hashtag.

What should you actually know about GLP-1s and facial changes?

If you're on semaglutide, tirzepatide, or another GLP-1 receptor agonist and you're noticing facial changes, here is what the evidence currently supports.

• Facial volume loss is a known consequence of significant weight loss, not a drug-specific side effect.
• Slower, more gradual weight loss may reduce the degree of skin laxity, though robust clinical data on this specifically for GLP-1 users is limited.
• Dermatologists and plastic surgeons have reported increased consultations for fillers and skin tightening procedures among GLP-1 users, but this is observational, not clinical trial data.
• The benefits of GLP-1 therapy on cardiometabolic health are well-documented and substantial. Facial aesthetics should be discussed with your prescribing clinician in the context of overall health goals, not as a reason to stop or avoid treatment.

If you have concerns about facial changes while on a GLP-1 medication, talk to your provider. That conversation belongs in a clinical setting, not in a comment section.

Bottom line on this video

There's no claim to fact-check here in any meaningful sense. The transcript is a production artifact, and the content, to the extent it exists, is a hashtag. The topic it gestures toward is real and worth discussing, but this video doesn't discuss it. It just tags along for the algorithmic ride.

"Ozempic face" is a real phenomenon rooted in real weight loss, backed by real science, and frequently misattributed in ways that could discourage patients from beneficial treatment. That deserves better than a German caption and a repeated sentence.